1
Clinical Trials associated with Allogeneic B7H3 CAR-γδT Cell(Peking University) / Not yet recruitingEarly Phase 1IIT Clinical Study of the Safety and Tolerability of B7H3 CAR-γδT Cell Injection in the Treatment of Advanced Solid Tumors
γδT cells can directly recognize non-peptide tumor antigens, such as IPP phosphorylated metabolites, without relying on specific major histocompatibility complexes (MHCs). This unique characteristic leads to a lower risk of graft-versus-host disease (GVHD). The clinical safety of γδT cells in allogeneic tumor therapies has been validated multiple times, highlighting their significant potential in developing universal CAR-T cell therapies.
B7H3 (CD276), a member of the B7 negative co-stimulatory molecule family, is minimally expressed or absent in normal tissues but highly expressed in various tumor tissues. As a result, B7H3 is regarded as a highly promising tumor-associated antigen and a universal drug target with substantial therapeutic potential.
By utilizing γδT cells as carrier cells, the development of universal B7H3 CAR-γδT cell injections for advanced solid tumors can effectively address risks such as autologous cell preparation failure and treatment delays. This innovative approach offers a highly efficient solution for solid tumor treatment and holds great promise for advancing immunotherapy in this field
100 Clinical Results associated with Allogeneic B7H3 CAR-γδT Cell(Peking University)
100 Translational Medicine associated with Allogeneic B7H3 CAR-γδT Cell(Peking University)
100 Patents (Medical) associated with Allogeneic B7H3 CAR-γδT Cell(Peking University)
100 Deals associated with Allogeneic B7H3 CAR-γδT Cell(Peking University)